PhRMA member companies’ R&D investments reach record high of $102.3 billion in 2021

PhRMA member companies’ continued investment in research and development (R&D) has led to new medicines transforming human health. Innovative biopharmaceutical approaches to treating patients for a broad range of diseases, including chronic and rare conditions, as well as meeting urgent new health challenges like COVID-19 are making a positive impact.